endofocusFOCUS ЭндокринологияFOCUS. Endocrinology2713-01772713-0185ООО "Издательство "Перо"10.15829/2713-0177-2023-4-31endofocus-55Research ArticleСтатьиЦентральный несахарный диабет вследствие нейрогипофизита в периоде реконвалесценции после перенесенной COVID-19: представление клинического случая и обзор литературыDeveloping central diabetes insipidus following neurohypophysitis during the convalescent period after recovering from covid-19: presentation of a clinical case and literature reviewhttps://orcid.org/0000-0003-2283-8958СтаростинаЕ. А.StarostinaE. A.

врач-эндокринолог

Еvgenia A. Starostina – MD, Endocrinologist

colpakova.ev@mail.ruhttps://orcid.org/0009-0004-4524-3142ДрачукЕ. С.DrachukE. S.

клинический ординатор

Elizaveta S. Drachuk – MD, resident

sdr68@mail.ruhttps://orcid.org/0000-0001-9119-2447ПржиялковскаяЕ. Г.PrzhiyalkovskayaE. G.

к.м.н., заведующая отделением нейроэндокринологии

Elena G. Przhiyalkovskaya – MD, PhD, Head of the Department of Neuroendocrinology

przhiyalkovskaya.elena@gmail.comhttps://orcid.org/0000-0001-6388-1544ПлатоноваН. М.PlatonovaN. M.

 д.м.н., заведующая отделом терапевтической эндокринологии

Nadezhda M. Platonova – MD, PhD, Head of the Department of Therapeutic Endocrinology

doc-platonova@inbox.ruhttps://orcid.org/0000-0002-8520-8702ТрошинаЕ. А.TroshinaE. A.

д.м.н., профессор, член-корр. РАН, заместитель директора

Ekaterina A. Troshina – MD, PhD, Professor, corresponding member RAS, Deputy Director

troshina@inbox.ruГНЦ ФГБУ «НМИЦ эндокринологии» МЗ РФEndocrinology research centre20231812202344Нейроэндокринология8288Copyright © Старостина Е.А., Драчук Е.С., Пржиялковская Е.Г., Платонова Н.М., Трошина Е.А., 20242024Старостина Е.А., Драчук Е.С., Пржиялковская Е.Г., Платонова Н.М., Трошина Е.А.Starostina E.A., Drachuk E.S., Przhiyalkovskaya E.G., Platonova N.M., Troshina E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://endofocus.elpub.ru/jour/article/view/55

В настоящее время имеется значительное количество исследований, посвященных влиянию SARS-CoV-2 на органы эндокринной системы. Однако данные, относящиеся к патологическим изменениям гипоталамо-гипофизарной системы в контексте COVID-19, остаются ограниченными. Гипофизит – общее понятие, охватывающее разнообразные воспалительные заболевания, поражающие гипофиз и приводящие к структурным изменениям в гипоталамо-гипофизарной оси и различным уровням гормональной недостаточности в передней и/или задней доле гипофиза.

В данной работе представлен клинический случай развития центрального несахарного диабета вследствие нейрогипофизита, проявившегося через два месяца после перенесенной новой коронавирусной инфекции SARS-CoV-2 (COVID-19). Наша работа способствует расширению знаний о редком, но потенциально возможном последствии новой коронавирусной инфекции, что имеет важное значение в свете высокой распространенности инфекции COVID-19.

Currently, there is a substantial body of research dedicated to exploring the impact of SARS-CoV-2 on the endocrine system. However, information regarding pathological changes in the hypothalamo-pituitary system in the context of COVID-19 remains limited. Hypophysitis is a general term encompassing various inflammatory conditions affecting the pituitary gland, leading to structural alterations in the hypothalamo-pituitary axis and various levels of hormonal deficiencies in the anterior and/or posterior pituitary.

This paper presents a clinical case of central diabetes insipidus resulting from neurohypophysitis, manifested two months after recovering from the novel coronavirus infection SARS-CoV-2 (COVID-19). Our study contributes to expanding knowledge about a rare but potentially consequential outcome of the novel coronavirus infection, which holds significance given the global prevalence of COVID-19. The unexpected consequences of SARS-CoV-2 infection contribute to maintaining caution among medical professionals and stimulate interest in scientific research.

ГипофизитнейрогипофизитSARS-CoV-2COVID-19центральный несахарный диабетHypophysitisneurohypophysitisSARS-CoV-2COVID-19central diabetes insipidusReferencesP. Caturegli, C. Newschaffer, A. Olivi, M. G. Pomper, P. C. Burger, and N. R. Rose, “Autoimmune Hypophysitis,” Endocr. Rev., vol. 26, no. 5, pp. 599–614, Aug. 2005, doi: 10.1210/er.2004-0011.P. Caturegli, C. Newschaffer, A. Olivi, M. G. Pomper, P. C. Burger, and N. R. Rose, “Autoimmune Hypophysitis,” Endocr. Rev., vol. 26, no. 5, pp. 599–614, Aug. 2005, doi: 10.1210/er.2004-0011.S. Gubbi, F. Hannah-Shmouni, C. A. Stratakis, and C. A. Koch, “Primary hypophysitis and other autoimmune disorders of the sellar and suprasellar regions,” Rev. Endocr. Metab. Disord., vol. 19, no. 4, pp. 335–347, Dec. 2018, doi: 10.1007/s11154-018-9480-1.S. Gubbi, F. Hannah-Shmouni, C. A. Stratakis, and C. A. Koch, “Primary hypophysitis and other autoimmune disorders of the sellar and suprasellar regions,” Rev. Endocr. Metab. Disord., vol. 19, no. 4, pp. 335–347, Dec. 2018, doi: 10.1007/s11154-018-9480-1.J. S. Gopal-Kothandapani, V. Bagga, S. B. Wharton, D. J. Connolly, S. Sinha, and P. J. Dimitri, “Xanthogranulomatous hypophysitis: a rare and often mistaken pituitary lesion,” Endocrinol. Diabetes Metab. Case Reports, vol. 2015, no. January, Jan. 2015, doi: 10.1530/EDM-14-0089.J. S. Gopal-Kothandapani, V. Bagga, S. B. Wharton, D. J. Connolly, S. Sinha, and P. J. Dimitri, “Xanthogranulomatous hypophysitis: a rare and often mistaken pituitary lesion,” Endocrinol. Diabetes Metab. Case Reports, vol. 2015, no. January, Jan. 2015, doi: 10.1530/EDM-14-0089.N. N. Imga, A. E. Yildirim, O. O. Baser, and D. Berker, “Clinical and hormonal characteristics of patients with different types of hypophysitis: a singlecenter experience,” Arch. Endocrinol. Metab., vol. 63, no. 1, pp. 47–52, Feb. 2019, doi: 10.20945/2359-3997000000102.N. N. Imga, A. E. Yildirim, O. O. Baser, and D. Berker, “Clinical and hormonal characteristics of patients with different types of hypophysitis: a singlecenter experience,” Arch. Endocrinol. Metab., vol. 63, no. 1, pp. 47–52, Feb. 2019, doi: 10.20945/2359-3997000000102.F. Amereller, A.-M. Küppers, K. Schilbach, J. Schopohl, and S. Störmann, “Clinical Characteristics of Primary Hypophysitis – A Single-Centre Series of 60 Cases,” Exp. Clin. Endocrinol. Diabetes, vol. 129, no. 03, pp. 234–240, Mar. 2021, doi: 10.1055/a-1163-7304.F. Amereller, A.-M. Küppers, K. Schilbach, J. Schopohl, and S. Störmann, “Clinical Characteristics of Primary Hypophysitis – A Single-Centre Series of 60 Cases,” Exp. Clin. Endocrinol. Diabetes, vol. 129, no. 03, pp. 234–240, Mar. 2021, doi: 10.1055/a-1163-7304.S. Wang et al., “Primary lymphocytic hypophysitis: Clinical characteristics and treatment of 50 cases in a single centre in China over 18 years,” Clin. Endocrinol. (Oxf)., vol. 87, no. 2, pp. 177–184, Aug. 2017, doi: 10.1111/cen.13354.S. Wang et al., “Primary lymphocytic hypophysitis: Clinical characteristics and treatment of 50 cases in a single centre in China over 18 years,” Clin. Endocrinol. (Oxf)., vol. 87, no. 2, pp. 177–184, Aug. 2017, doi: 10.1111/cen.13354.K. Tanonaka and T. Marunouchi, “Angiotensinconverting enzyme 2,” Folia Pharmacol. Jpn., vol. 147, no. 2, pp. 120–121, 2016, doi: 10.1254/fpj.147.120.K. Tanonaka and T. Marunouchi, “Angiotensinconverting enzyme 2,” Folia Pharmacol. Jpn., vol. 147, no. 2, pp. 120–121, 2016, doi: 10.1254/fpj.147.120.A. C. Walls, Y. Park, M. A. Tortorici, A. Wall, A. T. McGuire, and D. Veesler, “Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein,” Cell, vol. 181, no. 2, pp. 281–292.e6, Apr. 2020, doi: 10.1016/j.cell.2020.02.058.A. C. Walls, Y. Park, M. A. Tortorici, A. Wall, A. T. McGuire, and D. Veesler, “Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein,” Cell, vol. 181, no. 2, pp. 281–292.e6, Apr. 2020, doi: 10.1016/j.cell.2020.02.058.I. Glowacka et al., “Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63,” J. Virol., vol. 84, no. 2, pp. 1198–1205, Jan. 2010, doi: 10.1128/JVI.01248-09.I. Glowacka et al., “Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63,” J. Virol., vol. 84, no. 2, pp. 1198–1205, Jan. 2010, doi: 10.1128/JVI.01248-09.Y. Imai et al., “Angiotensinconverting enzyme 2 protects from severe acute lung failure,” Nature, vol. 436, no. 7047, pp. 112–116, Jul. 2005, doi: 10.1038/nature03712.Y. Imai et al., “Angiotensinconverting enzyme 2 protects from severe acute lung failure,” Nature, vol. 436, no. 7047, pp. 112–116, Jul. 2005, doi: 10.1038/nature03712.W. J. Welch, “Angiotensin II–Dependent Superoxide,” Hypertension, vol. 52, no. 1, pp. 51–56, Jul. 2008, doi: 10.1161/HYPERTENSIONAHA.107.090472.W. J. Welch, “Angiotensin II–Dependent Superoxide,” Hypertension, vol. 52, no. 1, pp. 51–56, Jul. 2008, doi: 10.1161/HYPERTENSIONAHA.107.090472.C. Marchesi, P. Paradis, and E. L. Schiffrin, “Role of the renin–angiotensin system in vascular inflammation,” Trends Pharmacol. Sci., vol. 29, no. 7, pp. 367–374, Jul. 2008, doi: 10.1016/j.tips.2008.05.003.C. Marchesi, P. Paradis, and E. L. Schiffrin, “Role of the renin–angiotensin system in vascular inflammation,” Trends Pharmacol. Sci., vol. 29, no. 7, pp. 367–374, Jul. 2008, doi: 10.1016/j.tips.2008.05.003.I. Hamming, W. Timens, M. Bulthuis, A. Lely, G. Navis, and H. van Goor, “Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis,” J. Pathol., vol. 203, no. 2, pp. 631–637, Jun. 2004, doi: 10.1002/path.1570.I. Hamming, W. Timens, M. Bulthuis, A. Lely, G. Navis, and H. van Goor, “Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis,” J. Pathol., vol. 203, no. 2, pp. 631–637, Jun. 2004, doi: 10.1002/path.1570.N. Chen et al., “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study,” Lancet, vol. 395, no. 10223, pp. 507–513, Feb. 2020, doi: 10.1016/S0140-6736(20)30211-7.N. Chen et al., “Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study,” Lancet, vol. 395, no. 10223, pp. 507–513, Feb. 2020, doi: 10.1016/S0140-6736(20)30211-7.T. Han, J. Kang, G. Li, J. Ge, and J. Gu, “Analysis of 2019-nCoV receptor ACE2 expression in different tissues and its significance study,” Ann. Transl. Med., vol. 8, no. 17, pp. 1077–1077, Sep. 2020, doi: 10.21037/atm-20-4281.T. Han, J. Kang, G. Li, J. Ge, and J. Gu, “Analysis of 2019-nCoV receptor ACE2 expression in different tissues and its significance study,” Ann. Transl. Med., vol. 8, no. 17, pp. 1077–1077, Sep. 2020, doi: 10.21037/atm-20-4281.Y. Ding et al., “Organ distribution of severe acute respiratory syndrome(SARS) associated coronavirus(SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways,” J. Pathol., vol. 203, no. 2, pp. 622–630, Jun. 2004, doi: 10.1002/path.1560.Y. Ding et al., “Organ distribution of severe acute respiratory syndrome(SARS) associated coronavirus(SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways,” J. Pathol., vol. 203, no. 2, pp. 622–630, Jun. 2004, doi: 10.1002/path.1560.A. M. Baig, A. Khaleeq, U. Ali, and H. Syeda, “Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms,” ACS Chem. Neurosci., vol. 11, no. 7, pp. 995–998, Apr. 2020, doi: 10.1021/acschemneuro.0c00122.A. M. Baig, A. Khaleeq, U. Ali, and H. Syeda, “Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host–Virus Interaction, and Proposed Neurotropic Mechanisms,” ACS Chem. Neurosci., vol. 11, no. 7, pp. 995–998, Apr. 2020, doi: 10.1021/acschemneuro.0c00122.A. Gutenberg, J. Larsen, I. Lupi, V. Rohde, and P. Caturegli, “A Radiologic Score to Distinguish Autoimmune Hypophysitis from Nonsecreting Pituitary Adenoma Preoperatively,” Am. J. Neuroradiol., vol. 30, no. 9, pp. 1766–1772, Oct. 2009, doi: 10.3174/ajnr.A1714.A. Gutenberg, J. Larsen, I. Lupi, V. Rohde, and P. Caturegli, “A Radiologic Score to Distinguish Autoimmune Hypophysitis from Nonsecreting Pituitary Adenoma Preoperatively,” Am. J. Neuroradiol., vol. 30, no. 9, pp. 1766–1772, Oct. 2009, doi: 10.3174/ajnr.A1714.Z. Karaca, F. Tanriverdi, K. Unluhizarci, F. Kelestimur, and H. Donmez, “Empty Sella may be the Final Outcome in Lymphocytic Hypophysitis,” Endocr. Res., vol. 34, no. 1–2, pp. 10–17, Jan. 2009, doi: 10.1080/07435800902841306.Z. Karaca, F. Tanriverdi, K. Unluhizarci, F. Kelestimur, and H. Donmez, “Empty Sella may be the Final Outcome in Lymphocytic Hypophysitis,” Endocr. Res., vol. 34, no. 1–2, pp. 10–17, Jan. 2009, doi: 10.1080/07435800902841306.S. Catford, Y. Y. Wang, and R. Wong, “Pituitary stalk lesions: systematic review and clinical guidance,” Clin. Endocrinol. (Oxf)., vol. 85, no. 4, pp. 507–521, Oct. 2016, doi: 10.1111/cen.13058.S. Catford, Y. Y. Wang, and R. Wong, “Pituitary stalk lesions: systematic review and clinical guidance,” Clin. Endocrinol. (Oxf)., vol. 85, no. 4, pp. 507–521, Oct. 2016, doi: 10.1111/cen.13058.M. Joshi, S. Gunawardena, A. Goenka, E. Ey, and G. Kumar, “Post COVID-19 Lymphocytic Hypophysitis: A Rare Presentation,” Child Neurol. Open, vol. 9, p. 2329048X2211030, Jan. 2022, doi: 10.1177/2329048X221103051.M. Joshi, S. Gunawardena, A. Goenka, E. Ey, and G. Kumar, “Post COVID-19 Lymphocytic Hypophysitis: A Rare Presentation,” Child Neurol. Open, vol. 9, p. 2329048X2211030, Jan. 2022, doi: 10.1177/2329048X221103051.J. Honegger et al., “Treatment of Primary Hypophysitis in Germany,” J. Clin. Endocrinol. Metab., vol. 100, no. 9, pp. 3460–3469, Sep. 2015, doi: 10.1210/jc.2015-2146.J. Honegger et al., “Treatment of Primary Hypophysitis in Germany,” J. Clin. Endocrinol. Metab., vol. 100, no. 9, pp. 3460–3469, Sep. 2015, doi: 10.1210/jc.2015-2146.B. Krishnappa et al., “Early Pulse Glucocorticoid Therapy and Improved Hormonal Outcomes in Primary Hypophysitis,” Neuroendocrinology, vol. 112, no. 2, pp. 186–195, 2022, doi: 10.1159/000516006.B. Krishnappa et al., “Early Pulse Glucocorticoid Therapy and Improved Hormonal Outcomes in Primary Hypophysitis,” Neuroendocrinology, vol. 112, no. 2, pp. 186–195, 2022, doi: 10.1159/000516006.G. A. Kaltsas et al., “Hypothalamo-Pituitary Abnormalities in Adult Patients with Langerhans Cell Histiocytosis: Clinical, Endocrinological, and Radiological Features and Response to Treatment,” J. Clin. Endocrinol. Metab., vol. 85, no. 4, pp. 1370–1376, Apr. 2000, doi: 10.1210/jcem.85.4.6501.G. A. Kaltsas et al., “Hypothalamo-Pituitary Abnormalities in Adult Patients with Langerhans Cell Histiocytosis: Clinical, Endocrinological, and Radiological Features and Response to Treatment,” J. Clin. Endocrinol. Metab., vol. 85, no. 4, pp. 1370–1376, Apr. 2000, doi: 10.1210/jcem.85.4.6501.C. Xu, A. Ricciuti, P. Caturegli, C. D. Keene, and A. Y. Kargi, “Autoimmune lymphocytic hypophysitis in association with autoimmune eye disease and sequential treatment with infliximab and rituximab,” Pituitary, vol. 18, no. 4, pp. 441–447, Aug. 2015, doi: 10.1007/s11102-014-0592-7.C. Xu, A. Ricciuti, P. Caturegli, C. D. Keene, and A. Y. Kargi, “Autoimmune lymphocytic hypophysitis in association with autoimmune eye disease and sequential treatment with infliximab and rituximab,” Pituitary, vol. 18, no. 4, pp. 441–447, Aug. 2015, doi: 10.1007/s11102-014-0592-7.S. Pekic et al., “Lymphocytic Hypophysitis Successfully Treated with Stereotactic Radiosurgery: Case Report and Review of the Literature,” J. Neurol. Surg. Part A Cent. Eur. Neurosurg., vol. 79, no. 01, pp. 077–085, Jan. 2018, doi: 10.1055/s-0037-1604079.S. Pekic et al., “Lymphocytic Hypophysitis Successfully Treated with Stereotactic Radiosurgery: Case Report and Review of the Literature,” J. Neurol. Surg. Part A Cent. Eur. Neurosurg., vol. 79, no. 01, pp. 077–085, Jan. 2018, doi: 10.1055/s-0037-1604079.A. B. Sheikh, M. A. Javaid, A. A. E. Sheikh, and R. Shekhar, “Central adrenal insufficiency and diabetes insipidus as potential endocrine manifestations of covid-19 infection: A case report,” Pan Afr. Med. J., vol. 38, 2021, doi: 10.11604/pamj.2021.38.222.28243.A. B. Sheikh, M. A. Javaid, A. A. E. Sheikh, and R. Shekhar, “Central adrenal insufficiency and diabetes insipidus as potential endocrine manifestations of covid-19 infection: A case report,” Pan Afr. Med. J., vol. 38, 2021, doi: 10.11604/pamj.2021.38.222.28243.P. Nonglait, R. Naik, and N. Raizada, “Hypophysitis after COVID-19 Infection,” Indian J. Endocrinol. Metab., vol. 25, no. 3, p. 255, 2021, doi: 10.4103/ijem.ijem_329_21.P. Nonglait, R. Naik, and N. Raizada, “Hypophysitis after COVID-19 Infection,” Indian J. Endocrinol. Metab., vol. 25, no. 3, p. 255, 2021, doi: 10.4103/ijem.ijem_329_21.R. A. Misgar, A. Rasool, A. I. Wani, and M. I. Bashir, “Central diabetes insipidus (Infundibuloneuro hypophysitis): A late complication of COVID-19 infection,” J. Endocrinol. Invest., vol. 44, no. 12, pp. 2855–2856, Dec. 2021, doi: 10.1007/s40618-021-01627-z.R. A. Misgar, A. Rasool, A. I. Wani, and M. I. Bashir, “Central diabetes insipidus (Infundibuloneuro hypophysitis): A late complication of COVID-19 infection,” J. Endocrinol. Invest., vol. 44, no. 12, pp. 2855–2856, Dec. 2021, doi: 10.1007/s40618-021-01627-z.

The authors declare that there are no conflicts of interest present.